诺和锐联合二甲双胍治疗妊娠期糖尿病的临床分析

Clinical Analysis of Nuovoray Combined with Metformin in the Treatment of Gestational Diabetes

目的探讨采用二甲双胍联合诺和锐治疗妊娠期糖尿病患者的临床效果。方法方便选择2018年1月—2020年3月该院收治的92例妊娠期糖尿病患者为研究对象,2018年1月—2019年1月收治的患者行二甲双胍治疗(二甲双胍组,47例),2019年2月—2020年3月收治的患者行二甲双胍+诺和锐联合药物治疗(联合药物组,45例),观察两组患者治疗依从性,治疗前及治疗1个月后、3个月后血糖、血脂水平,治疗3个月后患者不良事件发生率。结果治疗前两组患者血糖与血脂水平差异无统计学意义(P>0.05),采用不同方式治疗1、3个月后血糖与血脂水平均得到明显改善,其中联合药物组明显改善优于二甲双胍组;并联合药物组经过治疗后不良事件发生率17.78%、治疗依从性高达93.33%,在不良事件发生率方面差异无统计学意义(P>0.05),在治疗依从性上明显优于二甲双胍组,差异有统计学意义(χ^(2)=7.052,P<0.05)。结论针对妊娠期糖尿病患者可以采用二甲双胍+诺和锐联合药物治疗方式,使得患者不良事件发生率明显下降,提高患者治疗依从性,并有效改善患者血脂与血糖水平,有很高的应用价值。

Objective To explore the clinical effects of metformin combined with Novorazin in the treatment of patients with gestational diabetes.Methods Conveniently selected Ninety-two patients with gestational diabetes mellitus admitted to the hospital from January 2018 to March 2020 were selected as the research objects.Patients were treated with metformin from January 2018 to January 2019(metformin group,47 cases),and from February 2019 to March 2020,the patients underwent metformin+Novorazol combined drug therapy(combined drug group,45 cases).Observe the patient's treatment compliance,blood glucose and blood lipid levels before treatment,1 month after treatment,and 3 months after treatment,and the incidence of adverse events in patients after 3 months of treatment.Results Before treatment,there was no statistically significant difference in blood glucose and blood lipid levels between the two groups of patients(P>0.05).After 1 and 3 months of treatment with different methods,blood glucose and blood lipid levels were significantly improved,and the combined drug group was significantly better than the metformin group.In the combined drug group,the incidence of adverse events was 17.78%after treatment,and the treatment compliance was as high as 93.33%.There was no statistical significant difference in the incidence of adverse events(P>0.05),and the treatment compliance was significantly better than the metformin group,the difference was statistically significant(χ^(2)=7.052,P<0.05).Conclusion For patients with gestational diabetes,a combination of metformin+Novorazin can be used to significantly reduce the incidence of adverse events in patients,improve patient compliance with treatment,and effectively improve patients'blood lipids and blood glucose levels,which has high application value.